Probi has taken over all distribution of BLIS K12 and BLIS M18 in the US and Canada after Blis Technologies distribution agreement with its previous partner ended. Since 2021, Probi has had a partnership for the dairy-free production and distribution of Blis' products.
The technology transfer of the manufacturing has been completed, and Probi will be the sole distributor of bulk products for BLIS K12 and BLIS M18 on the North American market.
Since July 2021, Probi and Blis Technologies have a long-term strategic partnership for the distribution and manufacture of BLIS probiotic strains in oral health.
Blis Technologies has now ended the distribution agreement with a previous partner, which means that as of August 1, 2023, Probi will be the sole distributor of BLIS K12 and BLIS M18 ingredients in the USA and Canada.
We will be alone in the US with dairy-free oral probiotics, and we see great growth potential of the BLIS strains
Probi has also completed the technology transfer for the production of dairy-free BLIS K12 and BLIS M18 in their manufacturing facility in Redmond, Washington, which means that Probi has full-scale production capacity of both bulk powder and product applications of the strains.
“Oral health is a growing niche in probiotics. We will be alone in the US with dairy-free oral probiotics, and we see great growth potential of the BLIS strains. Our ability to offer customers both bulk powder and customised applications provide differentiated solutions to meet consumer demand," said Diane Alexander, North America Sales Director, Probi.
"Since 2021, we have had a close and very rewarding collaboration with Probi. We saw a need to consolidate our representation in the North American market and it was therefore natural to focus our distribution through Probi. Probi will work with our existing customers providing ongoing support and continuity of supply, this will include both the current source of BLIS K12 and BLIS M18 but also the option of dairy-free versions from the Probi facility," said Brian Watson, CEO of Blis Technologies.
Streptococcus salivarius BLIS K12 and Streptococcus salivarius BLIS M18 are part of a portfolio of clinically documented bacterial strains for supporting our natural immune defence and preventing infections of the mouth and throat. The BLIS strains also contribute to a healthy set of teeth and gums. Blis Technologies’ clinically documented strains have a successful history of use in New Zealand, Australia and Asia, as well as in Europe and in North America.